Deutsches Rotes Kreuz Gemeinnuetzige Krankenhaus GmbH Sachsen — Clinical Trial Site

13 Registered trials

7 Currently recruiting

Organisation

Deutsches Rotes Kreuz Gemeinnuetzige Krankenhaus GmbH Sachsen

Location

Chemnitz, Germany

Identifier

ORG-100025837

Address

Unritzstrasse 23, Rabenstein, 09117, Germany

Departments

-
Clinic of Dermatology
Department of Dermatology
Dermatology
Hautklinik
Klinik fuer Dermatologie

Clinical trials at this site (13)

Search interface

A multicenter, prospective, randomized, double blind, placebo controlled, adaptive design study performed to evaluate the efficacy and the s… Recruiting

2024-519623-23-00 Venous leg ulcer 5 2025-10-20
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2023-503904-10-00 Sjögren’s Syndrome With Moderate-to-severe Systemic Dis 5 2024-06-07
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome Recruiting

2023-507528-21-00 Gorlin Syndrome 5 2024-05-23
A Study to Assess the Long-Term Efficacy and Safety of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who participated in previou… Recruiting

2025-520771-59-00 Atopic Dermatitis 4 2026-02-03
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adoles… Recruiting

2024-518156-24-00 Atopic Dermatitis 5 2025-11-10
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2024-517513-32-00 Sjögren’s Syndrome 5 2025-05-16
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1) Recruiting

2022-500699-76-00 Active Systemic Lupus Erythematosus (SLE) 5 2023-05-18
A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Atopic Dermatitis Ended

2024-515494-95-00 Moderate to Severe Atopic Dermatitis (AD) 4 2025-05-26
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 2 (STOP-PN2) Ended

2024-511881-35-00 Prurigo Nodularis 5 2024-12-17
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended

2023-503923-24-00 Sjögren’s Syndrome With Moderate-toSevere Symptom State 5 2024-07-22
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo®… Ended

2023-507865-24-00 Advanced (unresectable/metastatic) melanoma 5 2025-03-28
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis Ended

2022-502997-18-00 Atopic Dermatitis 3 2024-02-02
Surgical or radiotherapeutic intervention concerning large singular stable to progressive metastases in patients with BRAFV600-mutated melan… Ended

2024-516073-74-00 Unresectable or metastatic melanoma with a BRAF V600 mu 6